<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14886">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01820208</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS- AH-01</org_study_id>
    <nct_id>NCT01820208</nct_id>
  </id_info>
  <brief_title>Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis</brief_title>
  <official_title>Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis. - A Double Blind Randomized Control Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <authority>India: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After successful screening, first the investigators first treat patients of severe alcoholic
      hepatitis with steroids for 7 days. Patients who are found to be unresponsive as per Lille's
      score [&gt;0.45] would be randomized into either placebo group or G-CSF group.  Responders to
      steroids will continue on steroids for 28 days followed by 2 weeks of tapering. Non
      responders will be randomized to receive G-CSF for 28days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of Survival of subjects in both group</measure>
    <time_frame>4 weeks and 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in Child's score in steroid unresponsive patients with severe alcoholic hepatitis patients</measure>
    <time_frame>4 weeks and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in child score at 4 week and 12 weeks compared to baseline in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in MELD score in steroid unresponsive patients with severe alcoholic hepatitis patients</measure>
    <time_frame>4 weeks and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in MELD score at 4 week and 12 weeks compared to baseline in both groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Severe Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)</description>
    <arm_group_label>G-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Severe alcoholic hepatitis patients [Maddrey's score &gt; 32] aged between 18 to 65 years.

        Exclusion Criteria:

          -  Presence of active infections

          -  Acute GI bleed

          -  Hepatorenal syndrome

          -  Patient unwilling

          -  DF&gt;120

          -  Autoimmune hepatitis

          -  Hepatitis B, Hepatitis C, HIV cases

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Shasthry SM, MD</last_name>
    <phone>+91-11-01146300000</phone>
    <email>shasthry@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Shasthry SM, MD</last_name>
      <phone>+91-11-01146300000</phone>
      <email>shasthry@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dr Ankit Bhardwaj</last_name>
      <phone>+91-11-01146300000</phone>
      <email>bhardwaj.ankit3@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>April 17, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
